Medical Engineering Department, Gansu Provincial Maternity and Child-care Hospital, Lanzhou, China.
Prenatal Diagnosis Center, Gansu Provincial Maternity and Child-care Hospital, Lanzhou, China.
BMJ Open. 2022 Mar 16;12(3):e053182. doi: 10.1136/bmjopen-2021-053182.
Network meta-analyses have confirmed that paclitaxel plus carboplatin could improve progression-free survival (PFS) and overall survival (OS) compared with platinum alone. However, detailed implementation schedule (weekly or 3-weekly therapy) was not specified in clinical practice guidelines. Evidence from studies is also inconsistent. We will conduct a systematic review and meta-analysis to evaluate the benefits and harms of weekly therapy and 3-weekly therapy of paclitaxel combined with carboplatin in women with ovarian cancer.
We will search PubMed, EMBASE and the Cochrane Library databases to include relevant randomised controlled trials comparing weekly therapy versus 3-weekly therapy of paclitaxel combined with carboplatin for women with ovarian cancer. Random-effects model will be used to pool data for patient-reported outcomes including survival rate, OS, PFS and adverse events. Grading of Recommendation, Assessment, Development and Evaluation approach will be used to rate the quality of evidence.
This systematic review and meta-analysis will be based on published data and does not therefore require specific ethical approval or consent for participation. The results will be published in a peer-reviewed journal.
10.17605/OSF.IO/GJUMA.
网络荟萃分析已经证实，与单独使用铂类药物相比，紫杉醇联合卡铂可提高无进展生存期（PFS）和总生存期（OS）。然而，临床实践指南并未具体规定详细的实施计划（每周或每 3 周治疗）。研究证据也不一致。我们将进行系统评价和荟萃分析，以评估紫杉醇联合卡铂每周治疗和每 3 周治疗在卵巢癌女性中的获益和危害。
我们将检索 PubMed、EMBASE 和 Cochrane 图书馆数据库，纳入比较紫杉醇联合卡铂每周治疗与每 3 周治疗卵巢癌女性的随机对照试验。将使用随机效应模型对包括生存率、OS、PFS 和不良事件在内的患者报告结局数据进行汇总。将使用推荐评估、制定与评价分级（Grading of Recommendation, Assessment, Development and Evaluation，GRADE）方法来评价证据质量。
本系统评价和荟萃分析将基于已发表的数据进行，因此不需要特定的伦理批准或参与同意。研究结果将发表在同行评议的期刊上。
OSF 注册号：10.17605/OSF.IO/GJUMA。
